Alaunos Therapeutics Reports Integrated Preclinical Data for Obesity Candidate ALN1003

On May 26, 2026, Alaunos Therapeutics reported an integrated preclinical readout for ALN1003, its oral, non-hormonal small-molecule candidate for obesity and metabolic disorders. The data consolidates findings from two non-GLP diet-induced obesity (DIO) mouse studies. In a 48-day study, ALN1003-treated mice showed a 10.3% reduction in body weight relative to controls, improved insulin sensitivity (lower HOMA-IR), and reduced liver weight by 43%. A shorter 18-day dose-ranging study demonstrated dose-dependent weight loss and favorable shifts in body composition (fat mass reduction). Blinded pathology reviews also suggested lower hepatic steatosis. Despite these positive signals, the company noted several limitations, including small sample sizes, dose aversion in drinking water administration, and mild, reversible hypolocomotion in some animals. Financially, Alaunos reported cash and cash equivalents of $0.354 million as of March 31, 2026, with a runway extending only into the second quarter of 2026. The company intends to pursue additional financing to fund further preclinical development, CMC activities, and the identification of next-generation analogs.